<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7361338\results\search\disease\results.xml">
  <result pre=", This article is being made freely available through PubMed" exact="Central" post="as part of the COVID-19 public health emergency response."/>
  <result pre="devices. The donation interval may vary between countries. Even though" exact="limited" post="published studies are not prospective or randomized, until the"/>
  <result pre="Apher. 2020;1â€&quot;7. 10.1002/jca.21806 1 INTRODUCTION At the end of 2019," exact="pneumonia" post="patients with an unidentified cause were started to be"/>
  <result pre="genetic analysis of the virus, it was understood that these" exact="pneumonia" post="cases were caused by the 2019 Novel Coronavirus (2019â€�nCoV).2"/>
  <result pre="the 2019 Novel Coronavirus (2019â€�nCoV).2 On 11 February 2020; the" exact="disease" post="was officially named as COVIDâ€�19, by the World Health"/>
  <result pre="number of comorbidities increases, the clinical outcome gets worse. Smoking," exact="chronic" post="obstructive pulmonary disease, diabetes, hypertension, cardiovascular diseases, and malignancy"/>
  <result pre="comorbidities increases, the clinical outcome gets worse. Smoking, chronic obstructive" exact="pulmonary" post="disease, diabetes, hypertension, cardiovascular diseases, and malignancy are reported"/>
  <result pre="outcome gets worse. Smoking, chronic obstructive pulmonary disease, diabetes, hypertension," exact="cardiovascular" post="diseases, and malignancy are reported to be the risk"/>
  <result pre="cases, it is important to find a treatment in a" exact="short" post="time. Passive antibody therapy involves administering antibodies against a"/>
  <result pre="a susceptible individual in order to protect or treat an" exact="infectious disease" post="associated with this agent. On the contrary, active vaccination"/>
  <result pre="susceptible individual in order to protect or treat an infectious" exact="disease" post="associated with this agent. On the contrary, active vaccination"/>
  <result pre="the 1890s and was the only method of treating some" exact="infectious diseases" post="before the development of antimicrobial therapy in the 1940s.6"/>
  <result pre="against many pathogens. Passive immunization obtained from sheep serum against" exact="diphtheria" post="toxin was first given to a child with diphtheria"/>
  <result pre="against diphtheria toxin was first given to a child with" exact="diphtheria" post="in 1891 and saved his life. German scientist Emil"/>
  <result pre="1901 Nobel Prize for his discovery of passive immunization against" exact="diphtheria" post="toxin. CPs have been used in epidemics of viral"/>
  <result pre="against diphtheria toxin. CPs have been used in epidemics of" exact="viral" post="infections like poliomyelitis, measles, mumps and flu.6 Experience in"/>
  <result pre="diphtheria toxin. CPs have been used in epidemics of viral" exact="infections" post="like poliomyelitis, measles, mumps and flu.6 Experience in the"/>
  <result pre="been used in epidemics of viral infections like poliomyelitis, measles," exact="mumps" post="and flu.6 Experience in the use of CP against"/>
  <result pre="in the use of CP against coronavirus was obtained from" exact="Severe" post="Acute Respiratory Syndrome 1 (SARSâ€�COVâ€�1) outbreaks in 2003. In"/>
  <result pre="the use of CP against coronavirus was obtained from Severe" exact="Acute" post="Respiratory Syndrome 1 (SARSâ€�COVâ€�1) outbreaks in 2003. In the"/>
  <result pre="use of CP against coronavirus was obtained from Severe Acute" exact="Respiratory" post="Syndrome 1 (SARSâ€�COVâ€�1) outbreaks in 2003. In the retrospective"/>
  <result pre="of CP against coronavirus was obtained from Severe Acute Respiratory" exact="Syndrome" post="1 (SARSâ€�COVâ€�1) outbreaks in 2003. In the retrospective nonâ€�randomized"/>
  <result pre="from the hospital (77.8% vs 23%; P = .004) and" exact="lower" post="mortality rate (0% vs 23.8%; P = .049) was"/>
  <result pre="14 of illness.10 CP was also used in the West" exact="African" post="Ebola epidemic in 2013. Eightyâ€�four patients received 500â€‰mL of"/>
  <result pre="CP was also reported in three patients with Middle East" exact="Respiratory" post="Syndrome (MERS) in South Korea. In this study, 3"/>
  <result pre="was also reported in three patients with Middle East Respiratory" exact="Syndrome" post="(MERS) in South Korea. In this study, 3 of"/>
  <result pre="Korea. In this study, 3 of 13 MERS patients with" exact="respiratory" post="failure received 4 CP infusions from recovered MERSâ€�CoVâ€�infected patients,"/>
  <result pre="patients, the body temperature normalized within 3â€‰days; the Sequential Organ" exact="Failure" post="Assessment Score decreased, and PaO2/FiO2 increased within 12â€‰days (range,"/>
  <result pre="PaO2/FiO2 increased within 12â€‰days (range, first 172â€�276 and then 284â€�366);" exact="viral" post="loads decreased and became negative within 12â€‰days; ELISA and"/>
  <result pre="within 12â€‰days; ELISA and neutralizing antibody titers increased. After 12â€‰days," exact="acute" post="respiratory distress syndrome (ARDS) improved in 4 patients (80%);"/>
  <result pre="12â€‰days; ELISA and neutralizing antibody titers increased. After 12â€‰days, acute" exact="respiratory" post="distress syndrome (ARDS) improved in 4 patients (80%); after"/>
  <result pre="and neutralizing antibody titers increased. After 12â€‰days, acute respiratory distress" exact="syndrome" post="(ARDS) improved in 4 patients (80%); after 2â€‰weeks, 3"/>
  <result pre="discharged from the hospital and the other two patients were" exact="stable" post="after 37â€‰days.14 In a recent study, researchers treated 10"/>
  <result pre="information suggests that CP administration is safe and reduces the" exact="viral" post="load. On March 24, the American Food and Drug"/>
  <result pre="safe and reduces the viral load. On March 24, the" exact="American" post="Food and Drug Administration (FDA) published a recommendation with"/>
  <result pre="administrations are carried out under the control of intensive care," exact="infectious disease" post="specialists and pulmonologists. 4 CONVALESCENT PLASMA: THE MECHANISM OF"/>
  <result pre="are carried out under the control of intensive care, infectious" exact="disease" post="specialists and pulmonologists. 4 CONVALESCENT PLASMA: THE MECHANISM OF"/>
  <result pre="revealed that the mechanism of action of CP in other" exact="viral" post="infections such as Ebola virus and Respiratory Syncytial Virus"/>
  <result pre="that the mechanism of action of CP in other viral" exact="infections" post="such as Ebola virus and Respiratory Syncytial Virus is"/>
  <result pre="CP in other viral infections such as Ebola virus and" exact="Respiratory" post="Syncytial Virus is mainly viral neutralization. The other mechanisms"/>
  <result pre="such as Ebola virus and Respiratory Syncytial Virus is mainly" exact="viral" post="neutralization. The other mechanisms are antibodyâ€�induced cellular cytotoxicity, complement"/>
  <result pre="Neutralizing antibodies delivered with CP can provide control of the" exact="viral" post="load. Nonâ€�neutralizing antibodies may also contribute to prophylaxis and/or"/>
  <result pre="testing was not performed at the time COVIDâ€�19 was suspected." exact="Complete" post="resolution of symptoms at least 14â€‰days prior to donation."/>
  <result pre="symptoms at least 14â€‰days prior to donation. Male donors, or" exact="female" post="donors who have not been pregnant, or female donors"/>
  <result pre="donors, or female donors who have not been pregnant, or" exact="female" post="donors who have been tested since their most recent"/>
  <result pre="be evaluated by all test required for normal blood donation." exact="Female" post="donors with a history of pregnancy should be screened"/>
  <result pre="screened for HLA antibodies to minimize the risk of transfusionâ€�related" exact="acute" post="lung injury (TRALI). In addition, a blood sample should"/>
  <result pre="have not been optimally validated. In addition, the relationship between" exact="total" post="antiâ€�SARSâ€�CoVâ€�2 antibodies and neutralizing antiâ€�SARSâ€�CoVâ€�2 antibodies is not clear."/>
  <result pre="is not clear. There is also uncertainty as to whether" exact="total" post="antibodies or subclasses (eg, IgM, IgG, or IgA) are"/>
  <result pre="the optimal measures, and which antigen is most informative.21, 22" exact="Limited" post="data are currently available on the ELISAs. In a"/>
  <result pre="conducted in 173 patients with COVIDâ€�19, the seroconversion rate for" exact="total" post="antibodies (Ab), IgM and IgG was 93.1%, 82.7%, and"/>
  <result pre="93.1%, 82.7%, and 64.7%, respectively. The median seroconversion time for" exact="total" post="Ab, IgM and then IgG were dayâ€�11, dayâ€�12 and"/>
  <result pre="an alternative matched unit is not available.16 5.3 Donor recruitment" exact="Blood" post="centers may play a role in recruitment of donors"/>
  <result pre="should be collected by apheresis to take larger volumes in" exact="short" post="intervals. Approximately 200â€�600â€‰mL plasma can be collected with apheresis"/>
  <result pre="plasma can be collected with apheresis devices depending on the" exact="total" post="blood volume of the donor. The collected plasma volume"/>
  <result pre="dose by body weight should be used. COVIDâ€�19 is rarely" exact="symptomatic" post="in the pediatric age group. Therefore, every procedure in"/>
  <result pre="to patients who met the following criteria16: Laboratory confirmed COVIDâ€�19" exact="Severe" post="or immediately lifeâ€�threatening COVIDâ€�19. Severe disease is defined as"/>
  <result pre="following criteria16: Laboratory confirmed COVIDâ€�19 Severe or immediately lifeâ€�threatening COVIDâ€�19." exact="Severe" post="disease is defined as one or more of the"/>
  <result pre="criteria16: Laboratory confirmed COVIDâ€�19 Severe or immediately lifeâ€�threatening COVIDâ€�19. Severe" exact="disease" post="is defined as one or more of the following:"/>
  <result pre="oxygen saturationâ€‰â‰¤â€‰93%, PaO2/FiO2â€‰ lung infiltrates &amp;gt;50% within 24â€�48â€‰hours The lifeâ€�threatening" exact="disease" post="is defined as one or more of the following:"/>
  <result pre="disease is defined as one or more of the following:" exact="respiratory" post="failure, septic shock, multiple organ dysfunction 8 PROPHYLAXIS There"/>
  <result pre="defined as one or more of the following: respiratory failure," exact="septic shock," post="multiple organ dysfunction 8 PROPHYLAXIS There is no clear"/>
  <result pre="of CP administration are similar to those of standard plasma." exact="Infection" post="with another infectious disease agent (viral transmission or bacterial"/>
  <result pre="are similar to those of standard plasma. Infection with another" exact="infectious disease" post="agent (viral transmission or bacterial contamination), immunological reactions such"/>
  <result pre="similar to those of standard plasma. Infection with another infectious" exact="disease" post="agent (viral transmission or bacterial contamination), immunological reactions such"/>
  <result pre="plasma. Infection with another infectious disease agent (viral transmission or" exact="bacterial" post="contamination), immunological reactions such as serum disease, nonâ€�hemolytic transfusion"/>
  <result pre="any complications related to CP.8 In developed countries, for HIV," exact="hepatitis" post="B and hepatitis C viruses, the risk of transfusionâ€�transmissible"/>
  <result pre="to CP.8 In developed countries, for HIV, hepatitis B and" exact="hepatitis C" post="viruses, the risk of transfusionâ€�transmissible infection is less than"/>
  <result pre="hepatitis B and hepatitis C viruses, the risk of transfusionâ€�transmissible" exact="infection" post="is less than one infection per two million donations.34"/>
  <result pre="viruses, the risk of transfusionâ€�transmissible infection is less than one" exact="infection" post="per two million donations.34 The risk of TRALI is"/>
  <result pre="because most of the critically ill patients have ARDS and" exact="disseminated intravascular coagulation." post="Both of these situations are risk factors for the"/>
  <result pre="ill patients are already infected. In addition, only 1% of" exact="symptomatic" post="patients have been reported to have detectable SARSâ€�CoVâ€�2 RNA"/>
  <result pre="an antibodyâ€�dependent enhancement (ADE). Antibodies that developed during a previous" exact="infectious disease" post="caused by a different viral serotype may exacerbate clinical"/>
  <result pre="antibodyâ€�dependent enhancement (ADE). Antibodies that developed during a previous infectious" exact="disease" post="caused by a different viral serotype may exacerbate clinical"/>
  <result pre="developed during a previous infectious disease caused by a different" exact="viral" post="serotype may exacerbate clinical severity.39 Previous infection with other"/>
  <result pre="by a different viral serotype may exacerbate clinical severity.39 Previous" exact="infection" post="with other types of coronavirus may arise the concern"/>
  <result pre="risk of ADE in COVIDâ€�19 and the geographic variation in" exact="disease" post="severity may be attributed to this mechanism.40 In the"/>
  <result pre="SARSâ€�CoVâ€�2 continues to spread worldwide. The exact treatment of COVIDâ€�19" exact="disease" post="is currently unknown. Even though limited published studies are"/>
  <result pre="exact treatment of COVIDâ€�19 disease is currently unknown. Even though" exact="limited" post="published studies are not prospective or randomized, until the"/>
  <result pre=". The World Health Organization (WHO) has officially named the" exact="disease" post="caused by the novel coronavirus as COVIDâ€�19. https://www.who.int/emergencies/diseases/novel-coronavirus-2019. Accessed"/>
  <result pre="Accessed on April 17, 2020. 4GorbalenyaAE, BakerSC, BaricRS, et al." exact="Severe" post="acute respiratory syndromeâ€�related coronavirus: the species and its viruses"/>
  <result pre="on April 17, 2020. 4GorbalenyaAE, BakerSC, BaricRS, et al. Severe" exact="acute" post="respiratory syndromeâ€�related coronavirus: the species and its viruses â€�"/>
  <result pre="April 17, 2020. 4GorbalenyaAE, BakerSC, BaricRS, et al. Severe acute" exact="respiratory" post="syndromeâ€�related coronavirus: the species and its viruses â€� a"/>
  <result pre="AmbrosinoDM. History of passive antibody administration forprevention and treatment of" exact="infectious diseases." post="Curr Opin HIV AIDS. 2015;10:129â€�134.25760933 7BlochEM, ShohamS, CasadevallA, et"/>
  <result pre="SiuLK, et al. Experience of using convalescent plasma for severeacute" exact="respiratory" post="syndrome among healthcare workers in a Taiwan hospital. J"/>
  <result pre="et al. Experience of using convalescent plasma for severeacute respiratory" exact="syndrome" post="among healthcare workers in a Taiwan hospital. J Antimicrob"/>
  <result pre="LamballerieX, et al. Evaluation of convalescent plasma for Ebola virus" exact="disease" post="in Guinea. N Engl J Med. 2016;374:33â€�42.26735992 12KoJH, SeokH,"/>
  <result pre="al. Challenges of convalescent plasma infusion therapy in Middle East" exact="respiratory" post="coronavirusinfection: a single centre experience. Antivir Ther. 2018;23:617â€�622.29923831 13ArabiYM,"/>
  <result pre="ErpEA, LuytjesW, FerwerdaG, van KasterenPB. Fcâ€�mediated antibody effector functions during" exact="respiratory" post="syncytial virus infection and disease. Front Immunol. 2019;10:548.30967872 19GunnBM,"/>
  <result pre="FerwerdaG, van KasterenPB. Fcâ€�mediated antibody effector functions during respiratory syncytial" exact="virus infection" post="and disease. Front Immunol. 2019;10:548.30967872 19GunnBM, YuWH, KarimMM, et"/>
  <result pre="van KasterenPB. Fcâ€�mediated antibody effector functions during respiratory syncytial virus" exact="infection" post="and disease. Front Immunol. 2019;10:548.30967872 19GunnBM, YuWH, KarimMM, et"/>
  <result pre="application of a rapid IgMâ€�IgG combined antibody test for SARSâ€�CoVâ€�2" exact="infection" post="diagnosis. J Med Virol. 202010.1002/jmv.25727. 24GuoL, RenL, YangS, et"/>
  <result pre="et al. Profiling early humoral response to diagnose novel coronavirus" exact="disease" post="(COVIDâ€�19). Clin Infect Dis. 2020 pii: ciaa310. 10.1093/cid/ciaa310. 25DuanK,"/>
  <result pre="LiC, et al. The Feasibility of Convalescent Plasma Therapy in" exact="Severe" post="COVIDâ€�19 Patientss:a Pilot Study. medRxiv. 202010.1101/2020.03.16.20036145. 26ZhaoJ, YuanQ, WangH,"/>
  <result pre="Patientss:a Pilot Study. medRxiv. 202010.1101/2020.03.16.20036145. 26ZhaoJ, YuanQ, WangH, et al." exact="Antibody" post="responses to SARSâ€�CoVâ€�2 in patients of novel coronavirus disease"/>
  <result pre="al. Antibody responses to SARSâ€�CoVâ€�2 in patients of novel coronavirus" exact="disease" post="2019. Clin Infect Dis. 202010.1093/cid/ciaa344. 27CasadevallA, ScharffMD. Return to"/>
  <result pre="ScharffMD. Return to the past: the case for antibodyâ€�basedtherapies in" exact="infectious diseases." post="Clin Infect Dis. 1995;21:150â€�161.7578724 28CasadevallA. Passive antibody administration (immediate"/>
  <result pre="Immunol. 2003;24:474â€�478.12967670 31CasadevallA, ScharffMD. Serum therapy revisited: animal models of" exact="infection" post="and development of passive antibody therapy. Antimicrob Agents Chemother."/>
  <result pre="1994;38:1695â€�1702.7985997 32RijndersB. Convalescent plasma as therapy for Covidâ€�19 severe SARSâ€�CoVâ€�2" exact="disease" post="(CONCOVID study) (ConCoVidâ€�19). ClinicalTrialsgov Identifier: NCT04342182 33HendricksonJE, HillyerCD. Noninfectious"/>
  <result pre="of clinical specimens. Jama. 2020;323(18):184310.1001/jama.2020.3786. 38ChangL, ZhaoL, GongH, WangL, WangL." exact="Severe" post="acute respiratory SyndromeCoronavirus 2 RNA detected in blood donations."/>
  <result pre="clinical specimens. Jama. 2020;323(18):184310.1001/jama.2020.3786. 38ChangL, ZhaoL, GongH, WangL, WangL. Severe" exact="acute" post="respiratory SyndromeCoronavirus 2 RNA detected in blood donations. Emerg"/>
  <result pre="specimens. Jama. 2020;323(18):184310.1001/jama.2020.3786. 38ChangL, ZhaoL, GongH, WangL, WangL. Severe acute" exact="respiratory" post="SyndromeCoronavirus 2 RNA detected in blood donations. Emerg Infect"/>
  <result pre="2020;26(7):1631â€&quot;1633. 10.3201/eid2607.200839.32243255 39KatzelnickLC, GreshL, HalloranME, et al. Antibodyâ€�dependent enhancement of" exact="severe dengue" post="disease in humans. Science. 2017;358:929â€�932.29097492 40TetroJA. Is COVIDâ€�19 receiving"/>
  <result pre="10.3201/eid2607.200839.32243255 39KatzelnickLC, GreshL, HalloranME, et al. Antibodyâ€�dependent enhancement of severe" exact="dengue disease" post="in humans. Science. 2017;358:929â€�932.29097492 40TetroJA. Is COVIDâ€�19 receiving ADE"/>
  <result pre="39KatzelnickLC, GreshL, HalloranME, et al. Antibodyâ€�dependent enhancement of severe dengue" exact="disease" post="in humans. Science. 2017;358:929â€�932.29097492 40TetroJA. Is COVIDâ€�19 receiving ADE"/>
 </snippets>
</snippetsTree>
